User:Mr. Ibrahem/Levomilnacipran

Levomilnacipran, sold under the brand name Fetzima, is an antidepressant used to treat major depressive disorder. While not approved for fibromyalgia, the similar medication milnacipran is. It is taken by mouth.

Common side effects include nausea, constipation, increased sweating, sexual dysfunction, and palpitations. Other side effects may include suicide in those under 25 years, serotonin syndrome, high blood pressure, bleeding, mania, and urinary retention. Safety in pregnancy is unclear. It is a serotonin–norepinephrine reuptake inhibitor (SNRI) and an enantiomer of milnacipran.

Levomilnacipran was approved for medical use in the United States in 2013 and Canada in 2015. Approval was rejected in Australia in 2016 and has not been applied for in Europe. In the United States it cost about 430 USD per month as of 2021.